Table 2.
Number of cells (mean ± SEM) in each tissue compartment 7 days after the last booster vaccination among AL and AL+EX mice
| Tissue | Treatment group | Total cell number | CD3+ | CD3+CD4+ | CD3+CD8+ | CD19+ or B220+a | NK1.1+ | CD11b+I-Ab+ | CD11c+I-Ab+ |
|---|---|---|---|---|---|---|---|---|---|
| ———(X 106)——— | ———(X 105)——— | ||||||||
| i.n. vaccination | |||||||||
| Peyer’s patchesb | AL | 11.0 ± 0.3 | 2.6 ± 0.2 | 1.3 ± 0.1 | 0.8 ± 0.1 | 8.4 ± 0.2 | 0.3 ± 0.1 | 1.4 ± 0.1 | 2.0 ± 0.1 |
| AL+EX | 12.0 ± 1.8 | 2.5 ± 0.5 | 1.3 ± 0.2 | 0.8 ± 0.1 | 9.1 ± 1.3 | 0.3 ± 0.2 | 2.1 ± 0.4 | 3.1 ± 0.6 | |
| mesenteric lymph nodesb | AL | 26.7 ± 2.2 | 13.1 ± 1.1 | 7.5 ± 0.7 | 5.9 ± 0.6 | 12.4 ± 1.4 | 11.1 ± 2.8 | 12.2 ± 1.1 | 9.4 ± 0.8 |
| AL+EX | 23.8 ± 6.6 | 15.0 ± 4.7 | 8.3 ± 2.8 | 7.0 ± 2.0 | 7.7 ± 1.8 | 12.7 ± 4.1 | 10.9 ± 2.7 | 7.8 ± 1.1 | |
| spleenc | AL | 106.8 ± 7.7 | 37.3 ± 3.1 | 22.9 ± 2.1 | 16.8 ± 1.5 | 52.8 ± 5.9 | 74.3 ± 6.9 | 32.7 ± 2.5 | 22.1 ± 2.6 |
| AL+EX | 86.3 ± 7.5 | 35.9 ± 3.8 | 20.7 ± 2.2 | 16.1 ± 1.8 | 49.1 ± 5.9 | 62.4 ± 7.6 | 21.3 ± 1.7 | 18.0 ± 1.2 | |
| s.c. vaccination | |||||||||
| inguinal lymph nodesd | AL | 23.0 ± 2.9 | 15.5 ± 1.8 | 8.6 ± 1.1 | 6.9 ± 0.7 | 5.7 ± 0.9 | 3.0 ± 0.3 | 3.6 ± 0.4 | 3.2 ± 0.4 |
| AL+EX | 20.3 ± 2.7 | 14.0 ± 1.9 | 7.6 ± 1.1 | 6.4 ± 0.8 | 4.6 ± 0.7 | 2.8 ± 0.6 | 3.3 ± 0.5 | 3.0 ± 0.5 | |
| spleene | AL | 131.5 ± 9.0 | 49.4 ± 5.2 | 29.1 ± 2.5 | 20.3 ± 2.9 | 64.7 ± 3.2 | 58.4 ± 2.3 | 30.8 ± 5.0 | 25.8 ± 5.0 |
| AL+EX | 100.8 ± 12.5 | 39.9 ± 4.0 | 22.9 ± 2.3 | 16.9 ± 1.7 | 53.4 ± 5.1 | 53.7 ± 4.1 | 41.8 ± 5.7 | 23.2 ± 3.9 | |
a
Anti-CD19 antibodies were used to identify B cells in the lymph nodes and spleen; anti-B220 antibodies were used to identify B cells in the Peyer’s patches.
b
n = 5 pooled groups of 2 mice per group.
c
n = 10 individual mice per group.
d
n = 3 pooled groups of 2 mice per group.
e
n = 6 individual mice per group.